Synthesis and biological activities of 14-epi-MART-10 and 14-epi-MART-11: Implications for cancer and osteoporosis treatment

Anticancer Research

Volumn 29, Issue 9, 2009, Pages 3563-3569

  Kittaka, Atsushi ^a   Hara, Hideki ^a   Takano, Masashi ^a   Sawada, Daisuke ^a   Arai, Midori A ^a   Takagi, Kenichiro ^b   Chida, Takayuki ^b   Harada, Yoshifumi ^b   Saito, Hiroshi ^b   Takenouchi, Kazuya ^b   Ishizuka, Seiichi ^b   Hayashi, Keiko ^c   Ikushiro, Shinichi ^c   Sakaki, Toshiyuki ^c   Sugiura, Takayuki ^a   Chen, Tai C ^d  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIJIN PHARMA LIMITED   (Japan)

^c TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

14 epi MART 10; 19 norvitamin D3; HL 60 cells; Julia coupling; PZ HPV 7 cells; Synthesis

Indexed keywords

2ALPHA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXY 19 NORVITAMIN D3; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; MART 10; MART 11; OSTEOCALCIN; QUINIC ACID; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CANCER RESEARCH; CELL STRAIN HL 60; CHEMICAL REACTION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESEARCH; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR OVERHAUSER EFFECT; OSTEOBLAST; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY;

ANIMALS; BONE DENSITY; CELL DIFFERENTIATION; CHOLECALCIFEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; FEMALE; HL-60 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; OSTEOCALCIN; OSTEOPOROSIS; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; TRANSCRIPTIONAL ACTIVATION;

EID: 68549118800     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. 3 analogs (Deltanoids). In: Vitamin D, 2nd ed., Feldman D, Pike JW and Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1405-1422, 2005.
2. Binderup L, Binderup E, Godtfredsen WO and Kissmeyer A-M: Development of new vitamin D analogs. In: Vitamin D, 2nd ed., Feldman D, Pike JW and Glorieux FH (eds.). New York, Elsevier Academic Press, pp. 1489-1510, 2005.
3. 3 analogs stabilize helix 12 of the vitamin D receptor. Chem Biol 15: 1029-1034, 2008.
4. DeLuca HF: Evolution of our understanding of vitamin D. Nutrition Rev 66(Suppl. 2): S73-S87, 2008.
5. 3. J Med Chem 52: 2204-2213, 2009.
6. Brown AJ and Slatopolsky E: Vitamin D analogs: therapeutic applications and mechanisms. Mol Asp Med 29: 433-452, 2008.
7. Yamada S, Shimizu M and Yamamoto K: Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Med Res Rev 23: 89-115, 2003. (Pubitemid 36024909)
8. 3: design and synthesis of VDR-agonists and antagonists with high biological activity. Curr Top Med Chem 6: 1273-1288, 2006.
9. 3 including 2-epi-ED-71 and its 20-epimers with HL-60 cell differentiation activity. J Org Chem 69: 7463-7471, 2004. (Pubitemid 39403331)
10. 3 in transcriptional regulation and human promyelocytic leukemia (HL-60) cell proliferation and differentiation. Biol Pharm Bull 29: 2246-2250, 2006. (Pubitemid 44690950)
11. Kittaka A: Structural refinement of seco-steroidal skeleton and the biological activity through nuclear receptors. Yakugaku Zasshi 128: 1235-1250, 2008.
12. 3 analogues as agonists of the mutant vitamin D receptor (Arg274Leu). Bioorg Med Chem 16: 3002-3024, 2008.
13. Saito N and Kittaka A: Highly potent vitamin D antagonists: design, synthesis and biological evaluation. ChemBioChem 7: 1478-1490, 2006. (Pubitemid 44555993)
14. 3-26,23-lactones. J Med Chem 49: 7063-7075, 2006. (Pubitemid 44885994)
15. 3-26,23-lactone. J Synth Org Chem Japan 65: 947-958, 2007.
16. 3 with selected 2α-substituted analogues. J Med Chem 49: 5199-5205, 2006. (Pubitemid 44260215)
17. 3: synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. J Med Chem 45: 3366-3380, 2002. (Pubitemid 34824025)
18. 3 (2MD): synthesis and biological evaluation. Bioorg Med Chem 17: 1747-1763, 2009.
19. 3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. J Org Chem 83: 7407-7415, 2003. (Pubitemid 37122492)
20. 3: efficient synthesis with Julia olefination, evaluation of biological activity, and development of new analyzing system for co-activator recruitment. Anticancer Res 26: 2621-2632, 2006.
21. 3 analogs as therapeutic agents for prostate cancer. J Steroid Biochem Mol Biol 103: 717-720, 2007. (Pubitemid 46401314)
22. Zhou X, Zhu G-D, Van Haver D, Vandewalle M, De Clercq PJ, Verstuyf A and Bouillon R: Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1α,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. J Med Chem 42: 3539-3556, 1999. (Pubitemid 29445089)
23. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60: 2673-2679, 2000. (Pubitemid 30318243)
24. Eelen G, Verlinden L, Rochel N, Claessens F, De Clercq P, Vandewalle M, Tocchini-Valentini G, Moras D, Bouillon R and Verstuyf A: Superagonistic action of 14-epi analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol Pharmacol 67: 1566-1573, 2005. (Pubitemid 40594155)
25. 3 analogues. Syn Lett 8: 1175-1179, 2003. (Pubitemid 36793708)
26. 3. Bioorg Med Chem Lett 5: 159-162, 1995.
27. 3: synthesis, isomerization to previtamins, and biological studies. J Med Chem 37: 2387-2393, 1994.
28. 3 to chick intestinal receptor. Steroids 37: 33-43, 1981. (Pubitemid 11133126)
29. Collins SJ, Ruscetti FW, Gallagher RE and Gallo RC: Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethy!sulfoxide. J Exp Med 149: 969-974, 1979.
30. Ozono K, Liao J, Kerner SA, Scott RA and Pike JW: The vitamin D-responsive element in the human osteocalcin promoter. J Biol Chem 265: 21881-21888, 1990.
31. 3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes. J Invest Dermatol 104: 113-117, 1995.